This is the second milestone reached in the collaboration, in which Galapagos has agreed to discover and validate novel drug targets for Wyeth. Under the terms of the 2003 agreement, Galapagos could receive milestone payments of up to E30 million from the collaboration. The targets involved in the Wyeth collaboration are unrelated to the suite of proprietary validated targets in Galapagos’ own osteoporosis program.
“Wyeth licensing targets identified by Galapagos speaks to the strengths and uniqueness of our target discovery approach,” said Onno van de Stolpe, CEO of Galapagos. “The expertise which led to this milestone with Wyeth also forms the basis for our own portfolio of novel targets in osteoporosis.”